Visfatin Level and The Risk of Hypertension and Cerebrovascular Accident: A Systematic Review and Meta-Analysis

Abstract

High blood pressure is related with increased cerebrovascular accident. High visfatin / NAMPT(nicotinamide phosphoribosyltransferase) plasma levels may promote vascular inflammation and atherosclerotic plaque destabilization and have been evaluated as a marker for identifying stages of essential hypertension. However, its role in the pathogenesis of hypertension and cerebrovascular accident (CVA) is still uncertain. In order to review and meta-analyze observational studies investigating visfatin concentration and the risk for hypertension or CVA, a systematic search of PubMed, ovid EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) until December 07, 2016 was performed. After data extraction and quality assessment, a meta-analysis was performed using RevMan 5.3 and STATA 14.0. A total of 1693 adults from 8 studies for hypertension (974 with hypertension) and 1696 adults from 7 CVA studies (957 with CVA) were enrolled in the current meta-analysis. Cochran’s Q-statistic and I² test were applied to estimate the heterogeneity of the studies. The fixed-effects were used to compute the weighted mean difference in visfatin levels. Plasma visfatin concentration was much higher in hypertension and CVA patients than in healthy individuals. These evidences suggested the association of hypertension and CVA with higher plasma visfatin level.

Key words

visfatin - adipokine - hypertension - cerebrovascular accident

• References

• 1 Bekaert M, Verhelst X, Geerts A. et al. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: A systematic review. Obes Rev 2016; 17: 68-80
• 2 Sumner AE, Falkner B, Kushner H. et al. Relationship of leptin concentration to gender, menopause, age, diabetes, and fat mass in African Americans. Obes Res 1998; 6: 128-133
• 3 Berndt J, Kloting N, Kralisch S. et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916
• 4 Lovren F, Pan Y, Shukla PC. et al. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: Translational implications for atherosclerosis. Am J Physiol Endocrinol Metab 2009; 296: E1440-E1449
• 5 Kendal-Wright CE, Hubbard D, Bryant-Greenwood GD. Chronic stretching of amniotic epithelial cells increases pre-B cell colony-enhancing factor (PBEF/visfatin) expression and protects them from apoptosis. Placenta 2008; 29: 255-265
• 6 Adya R, Tan BK, Punn A. et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: Novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008; 78: 356-365
• 7 Liang Z, Wu Y, Xu J. et al. Correlations of serum visfatin and metabolisms of glucose and lipid in women with gestational diabetes mellitus. J Diabetes Investig 2016; 7: 247-252
• 8 Chen MP, Chung FM, Chang DM. et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299
• 9 Choi KM, Lee JS, Kim EJ. et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol 2008; 158: 203-207
• 10 Axelsson J, Witasp A, Carrero JJ. et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007; 49: 237-244
• 11 Sethi JK, Vidal-Puig A. Visfatin: The missing link between intra-abdominal obesity and diabetes?. Trends Mol Med 2005; 11: 344-347
• 12 Hognogi LD, Simiti LV. The cardiovascular impact of visfatin – An inflammation predictor biomarker in metabolic syndrome. Clujul Med 2016; 89: 322-326
• 13 Hsu CP, Yamamoto T, Oka S, Sadoshima J. The function of nicotinamide phosphoribosyltransferase in the heart. DNA Repair 2014; 23: 64-68
• 14 Burgos ES. NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism. Curr Med Chem 2011; 18: 1947-1961
• 15 Wang P, Du H, Zhang RY. et al. Circulating and local visfatin/Nampt/PBEF levels in spontaneously hypertensive rats, stroke-prone spontaneously hypertensive rats and Wistar-Kyoto rats. J Physiol Sci 2010; 60: 317-324
• 16 Lu LF, Yang SS, Wang CP. et al. Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke. J Stroke Cerebrovasc Dis 2009; 18: 354-359
• 17 Ozal E, Sahin I, Bolat I. et al. Visfatin levels are increased in patients with resistant hypertension and are correlated with left ventricular hypertrophy. Blood Press Monit 2017; 22: 137-142
• 18 Kim DH, Kim C, Ding EL. et al. Adiponectin levels and the risk of hypertension: A systematic review and meta-analysis. Hypertension 2013; 62: 27-32
• 19 Dogru T, Sonmez A, Tasci I. et al. Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J Hum Hypertens 2007; 21: 173-175
• 20 Xia K, Ding R, Yang Y. et al. [Association between serum leptin, adiponectin, visfatin, obesity and hypertension in female]. Zhonghua nei ke za zhi 2015; 54: 768-772
• 21 Horbal SR, Seffens W, Davis AR. et al. Associations of apelin, visfatin, and urinary 8-isoprostane with severe hypertension in African Americans: The MH-GRID Study. Am J Hypertens 2016; 29: 814-820
• 22 Kocelak P, Olszanecka-Glinianowicz M, Owczarek A. et al. Plasma visfatin/nicotinamide phosphoribosyltransferase levels in hypertensive elderly – results from the PolSenior substudy. J Am Soc Hypertens 2015; 9: 1-8
• 23 Gunes F, Akbal E, Cakir E. et al. Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients. Intern Med 2012; 51: 553-557
• 24 Liakos CI, Sanidas EA, Perrea DN. et al. Apelin and visfatin plasma levels in healthy individuals with high normal blood pressure. Am J Hypertens 2016; 29: 549-552
• 25 Rotkegel S, Chudek J, Spiechowicz-Zaton U. et al. The effect of sodium restricted diet on plasma visfatin levels in hypertensive patients with visceral obesity. Kidney Blood Press Res 2013; 37: 124-131
• 26 Andreeva AA. [Dynamics the level of visfatin and markers of immune inflammation in hypertensive patients with abdominal obesity using the combination of antihypertensive therapy]. Georgian Med News 2013; 72-77
• 27 Gu SJ, Xuan HF, Lu M. et al. Admission plasma visfatin level strongly correlates with hematoma growth and early neurologic deterioration in patients with acute spontaneous basal ganglia hemorrhage. Clin Chim Acta 2013; 425: 85-89
• 28 Huang Q, Dai WM, Jie YQ. et al. High concentrations of visfatin in the peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome. Peptides 2013; 39: 55-58
• 29 Wang JX, Hou Y, Ruan SP. et al. Plasma visfatin, a possible prognostic marker in aneurysmal subarachnoid hemorrhage. Peptides 2013; 50: 8-12
• 30 Kadoglou NP, Fotiadis G, Lambadiari V. et al. Serum levels of novel adipokines in patients with acute ischemic stroke: Potential contribution to diagnosis and prognosis. Peptides 2014; 57: 12-16
• 31 Yin CG, Jiang L, Tang B. et al. Prognostic significance of plasma visfatin levels in patients with ischemic stroke. Peptides 2013; 42: 101-104
• 32 Fukuhara A, Matsuda M, Nishizawa M. et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430
• 33 Wang P, Xu TY, Guan YF. et al. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: Role of nicotinamide mononucleotide. Cardiovasc Res 2009; 81: 370-380
• 34 Romacho T, Sanchez-Ferrer CF, Peiro C. Visfatin/Nampt: An adipokine with cardiovascular impact. Mediat Inflam 2013; 2013 946427
• 35 Faraco G, Iadecola C. Hypertension: A harbinger of stroke and dementia. Hypertension 2013; 62: 810-817
• 36 Zhao Y, Guan YF, Zhou XM. et al. Regenerative neurogenesis after ischemic stroke promoted by nicotinamide phosphoribosyltransferase-nicotinamide adenine dinucleotide cascade. Stroke 2015; 46: 1966-1974
• 37 Erfani S, Khaksari M, Oryan S. et al. Nampt/PBEF/visfatin exerts neuroprotective effects against ischemia/reperfusion injury via modulation of Bax/Bcl-2 ratio and prevention of caspase-3 activation. J Mol Neuroscience : MN 2015; 56: 237-243
• 38 Takebayashi K, Suetsugu M, Wakabayashi S. et al. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007; 56: 451-458
• 39 Meier FM, Frommer KW, Peters MA. et al. Visfatin/pre-B-cell colony-enhancing factor (PBEF), a proinflammatory and cell motility-changing factor in rheumatoid arthritis. J Biol Chem 2012; 287: 28378-28385
• 40 Kim SR, Bae YH, Bae SK. et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 2008; 1783: 886-895
• 41 Shi KL, Qian JY, Qi L. et al. Atorvastatin antagonizes the visfatin-induced expression of inflammatory mediators via the upregulation of NF-kappaB activation in HCAECs. Oncol Lett 2016; 12: 1438-1444
• 42 Romacho T, Azcutia V, Vazquez-Bella M. et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 2009; 52: 2455-2463
• 43 Xiao J, Xiao ZJ, Liu ZG. et al. Involvement of dimethylarginine dimethylaminohydrolase-2 in visfatin-enhanced angiogenic function of endothelial cells. Diabetes Metab Res Rev 2009; 25: 242-249
• 44 Kong Q, Xia M, Liang R, Li L, Cu X, Sun Z, Hu J. Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease. Singapore Med J 2014; 55: 383-387